Ambrx Biopharma American Performance
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
The firm shows a Beta (market volatility) of 1.41, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ambrx Biopharma will likely underperform. Ambrx Biopharma American right now shows a risk of 0.0%. Please confirm Ambrx Biopharma American value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Ambrx Biopharma American will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ambrx Biopharma American has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Ambrx Biopharma is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 51.9 M | |
| Free Cash Flow | -58.8 M |
Ambrx |
Ambrx Biopharma Relative Risk vs. Return Landscape
If you would invest 1,573 in Ambrx Biopharma American on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Ambrx Biopharma American or generate 0.0% return on investment over 90 days. Ambrx Biopharma American is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Ambrx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ambrx Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ambrx Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ambrx Biopharma American, and traders can use it to determine the average amount a Ambrx Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AMAM |
Based on monthly moving average Ambrx Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ambrx Biopharma by adding Ambrx Biopharma to a well-diversified portfolio.
Ambrx Biopharma Fundamentals Growth
Ambrx Stock prices reflect investors' perceptions of the future prospects and financial health of Ambrx Biopharma, and Ambrx Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ambrx Stock performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X | |||
| Price To Sales | 432.96 X | |||
| Revenue | 4.09 M | |||
| EBITDA | (61.75 M) | |||
| Cash And Equivalents | 110.89 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.98 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (57.7 M) | |||
| Earnings Per Share | 0.42 X | |||
| Total Asset | 146.98 M | |||
| Retained Earnings | (291.63 M) | |||
About Ambrx Biopharma Performance
By examining Ambrx Biopharma's fundamental ratios, stakeholders can obtain critical insights into Ambrx Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Ambrx Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company was incorporated in 2003 and is headquartered in La Jolla, California. Ambrx Biopharma operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 81 people.Things to note about Ambrx Biopharma American performance evaluation
Checking the ongoing alerts about Ambrx Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ambrx Biopharma American help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ambrx Biopharma is not yet fully synchronised with the market data | |
| Ambrx Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.09 M. Net Loss for the year was (67.06 M) with profit before overhead, payroll, taxes, and interest of 7.4 M. | |
| Ambrx Biopharma American currently holds about 110.89 M in cash with (57.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Ambrx Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ambrx Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Ambrx Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ambrx Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ambrx Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ambrx Biopharma's stock. These opinions can provide insight into Ambrx Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |